A total of 654 centers from 48 countries were contacted for the 2010 survey. In all, 634 centers reported a total of 33 362 hematopoietic SCT (HSCT) with 30 012 patients receiving their first transplant (12 276 allogeneic (41%) and 17 736 autologous (59%)). Main indications were leukemias: 9355 (31%; 93% allogeneic), lymphoid neoplasias specifically Non Hodgkin's lymphoma, Hodgkin's lymphoma and plasma cell disorders: 17 362 (58%; 12% allogeneic), solid tumors: 1585 (5%; 6% allogeneic) and nonmalignant disorders: 1609 (6%; 88% allogeneic). There were more unrelated donors than HLA-identical sibling donors (53% versus 41%); the proportion of peripheral blood as stem cell source was 99% for autologous and 71% for allogeneic HSCT. Cord blood was primarily used in allogeneic transplants (6% of total) with three autologous cord blood HSCT being reported. The number of transplants has increased by 19% since 2005 (allogeneic 37% and autologous 9%) and continued to increase by about 1100 HSCT per year since 2000. Patterns of increase were distinct and different. The data show the development of transplantation in Europe since 1990, with the number of patients receiving a HSCT increasing from 4200 to over 30 000 annually. The most impressive trend seen is the steady increase of unrelated donor transplantation, in parallel to the availability of unrelated donors through donor registries.
INTRODUCTION
Hematopoietic SCT (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. 1, 2 Forecasts predict an ongoing increase in the near future. 3, 4 The annual activity survey, describing the status of HSCT in Europe, has become an instrument used to observe trends and to monitor changes in technology use. 5, 6 The survey captures the numbers of HSCT performed in the preceding year from each participating team, split by indication, donor type and stem cell source. The standardized structure of the survey over many years and the excellent commitment by the participating teams allow us to observe changes over time and to evaluate factors associated with such changes. 6 More recently, the survey has included information on cellular transplants with hematopoietic stem cells for nonhematopoietic use, as well as on the use of non-hematopoietic stem and progenitor cells. 7 This coincides with the recent interest of the World Health Organization WHO (http://www.who.org) in cell and tissue transplants and further stresses the need for adequate and timely information. 8 The European Group of Blood and Marrow Transplantation (EBMT) analyses in previous years have shown an increase in the annual absolute HSCT numbers and transplant rates (number of HSCT/10 million inhabitants) of about 4-13% (median 8%) for allogeneic and of 1.5-9.5% (median 4%) for autologous HSCT, following earlier findings of the high predictability of transplant rates. 9, 10 This report is based on the 2010 survey data and, in addition, as the survey was started in 1990 and as this is an anniversary edition, data on the way transplants have evolved from 1990 to 2010 is shown. As there are differences in the availability of resources, governmental support and access of patients to HSCT, 11 we present differences among major European countries in transplant rates for different indications.
PATIENTS AND METHODS

Data collection and validation
Participating teams were requested to report data for 2010 by indication, stem cell source and donor type as listed in Table 1 . 5, 9 Quality control measures included several independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT Registry database, crosschecking with the National Registries and onsite visits of selected teams. 
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Transplant rates. Transplant rates, defined as numbers of HSCT per 10 million inhabitants, were computed for each country without adjustments for patients who crossed borders and received their HSCT in a foreign country. Population numbers were obtained from the US census bureau database (http://www.census.gov/population/international/data/idb/rank.php).
Analysis. Wherever appropriate, absolute numbers of transplanted patients, or transplants or transplant rates are shown for specific countries, indications or transplant techniques. Changes over time are depicted graphically. In seven large European countries (population 420 million) reporting to the survey, France, Germany, Italy, Poland, Spain, Turkey and the United Kingdom, descriptive comparisons of transplant rates for particular indications are presented. These countries were chosen in order to eliminate the impact that single transplant centers specializing in specific indications may have on these rates.
RESULTS
data
Participating teams in 2010. Of the 634 teams, 390 (62%) did both allogeneic and autologous transplants, 222 (35%) restricted their activity to autologous HSCT only and 14 teams (2%) to allogeneic transplants only. In all, 8 (1%) teams reported having performed no transplants in 2010.
Numbers of patients and transplants in 2010. A total of 30 012 patients were transplanted in 2010. Of these, the first transplant for 12 276 (41%) patients was allogeneic, whereas the first transplant for 17 736 (59%) patients was autologous. Furthermore, there were 2022 retransplants (959 allogeneic/1063 autologous) and 1328 multiple transplants (110 allogeneic/1218 autologous), bringing the total to 33 362 HSCT procedures, 13 345 allogeneic (40%) and 20 017 autologous (60%) performed in 2010.
Indications for HSCT in 2010. Indications for HSCT in 2010 are listed in detail in Table 1 and their distribution is illustrated in Figures 1 a and b: allogeneic HSCT and autologous HSCT, respectively. 13 Main indications were lymphoid neoplasias with 17 362 patients (58%): 1977 allogeneic (11%) and 15 385 autologous (89%), leukemias with 9355 patients (31%): 8685 allogeneic (93%) and 670 autologous (7%), solid tumors with 1585 patients (5%): 81 allogeneic (5%) and 1504 autologous (95%) and non-malignant disorders with 1609 patients (5%): 1449 allogeneic (90%) and 160 autologous (10%). Autologous HSCT for non-malignant disorders predominantly include patients with autoimmune disorders (n ¼ 148). An additional 101 patients (o1%), 84 with allogeneic HSCT and 17 with autologous HSCT, were listed as 'other indications'.
Stem cell source and donor type in 2010. There were clear differences in the use of stem cell source between autologous and allogeneic HSCT. Of the 20 017 autologous transplants, 185 (1%) were BMderived and 19 829 (99%) were derived from PBSCs or from combined peripheral blood and BM. There were three autologous HSCT reported with cord blood cells, one for a child with neuroblastoma, one for a child with SAA and one for a child with myelodysplastic syndome (MDS) transformed to acute leukemia (AL).
Of the 13 345 allogeneic transplants, 2 985 (22%) were BM, 9 519 (71%) were peripheral blood and 841 (6%) were cord blood transplants. Cord blood was used as stem cell source for 47 (0.9%) of HLA-identical siblings, 5 (0.6%) from other family members and 789 (11%) of unrelated donors. The highest incidence of cord blood transplants from unrelated donors was seen in France, Italy and Spain: 450 (22% of all unrelated HSCT). The choice of stem cell source differed by main indication for all types of allogeneic HSCT. BM remained the preferred source of stem cells for allogeneic transplants for non-malignant disorders (59%). 13 Donors for the 13 345 allogeneic HSCT were HLA-identical siblings (5359 (40%) BM or peripheral blood donors and 47 (0.35%) targeted cord blood HSCT), other family members (802 (6%)), syngeneic twin Among the seven large European countries (population 420 million) listed above, rates for allogeneic HSCT ranged from 74 transplants per 10 million population in Turkey to 348 in Germany. For autologous HSCT, the range was 93 in Turkey to 497 in Italy. Differences were even larger between countries when rates of unrelated donor transplants are compared (7 transplants per 10 million population in Turkey with 246 in Germany).
Indications for HSCT in the years 1990-2010 The first transplant activity survey was performed in 1990, where 143 teams from 20 countries reported their data by indication, donor type and stem cell source. In those early years, stem cells were collected from the BM and the techniques for collecting peripheral blood stem cells were being developed. In 1990, a total of 4234 patients were reported to the survey. Main indications were leukemias with 2377 patients (56%): 1621 allogeneic (68%) and 756 autologous (32%), lymphoid neoplasias with 1092 patients (26%): 144 allogeneic (13%) and 948 autologous (87%), solid tumors with 382 patients (9%): 5 allogeneic and 377 autologous and non-malignant disorders with 339 patients (8%): all allogeneic. An additional 44 patients (1%), 28 with allogeneic HSCT and 16 with autologous HSCT, were listed as 'other indications'. The main donor type was HLA-identical sibling (1956) . In addition, 181 HSCTs were performed from an unrelated donor primarily for leukemia or aplastic anemia.
Since 1990, the survey has been conducted annually. A gradual increase in the number of teams and countries, from 143 teams in 20 countries in 1990 to 634 teams in 45 countries (37 European and 8 affiliated countries) in 2010, allows a detailed observation of developing trends within the field of SCT (Figures 3a and b) .
Within the cumulative data, a total of 375 948 patients have been reported to the survey, 135 179 with an allogeneic first HSCT (36%) and 240 The main indications for allogeneic HSCT have shifted from CML and acute leukemia in 1990 to acute leukemia, myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS) and lymphoma in 2010. For autologous HSCT, the shift has been from lymphoma and acute leukemia to plasma cell disorders (PCDs) and lymphoma ( Figure 3 ). Allogeneic transplants for CML have stabilized at a rate of 400 transplants per year. The percentage of CML transplants done after transformation to accelerated phase as compared with chronic phase continues to increase (now at 255 in advanced disease versus 161 in chronic phase) despite recommendations to do these transplants in patients nonresponsive or intolerant to tyrosine kinase inhibitors while still in chronic phase.
Stem cell source and donor type from 1990-2010. There were clear differences in the use of stem cell source between autologous and allogeneic HSCT. Of the 240 769 autologous transplants, 19 320 (8%) were BM-derived and 221 443 (92%) were derived from PBSCs.
Of the 135 179 allogeneic transplants, 57 844 (43%) were BM, 74 000 (55%) were peripheral blood and 3335 (2%) were cord blood transplants. The annual number of cord blood transplants reached 844 in 2010.
In autologous HSCT, the switch from marrow to peripheral blood occurred in the early nineties and was almost complete, whereas the switch in allogeneic HSCT from marrow to peripheral blood occurred later and appears to have stabilized around 70%. In allogeneic HSCT, for non-malignant conditions, the use of marrow still predominates. After it has been shown in observational studies that peripheral blood was associated with more chronic GVHD and poor survival in patients with marrow failure, the trend is now to prefer marrow as a stem cell source for this indication. 14, 15 The use of marrow has increased from 48% in 2009 to 59% in 2010 for nonmalignant disorders.
Changes in the use of donors are shown in Figure 4 . It is evident that the use of unrelated donors is increasing more rapidly than that of sibling donors in Europe. Since 2008, the annual number of unrelated donor transplants exceeded that of identical sibling transplants, and in 2010, there were 30% more unrelated than HLAidentical sibling donor transplants (7098 unrelated HSCT versus 5406 HLA-identical siblings) done. Figures 5a and b show transplant rates for allogeneic and autologous transplants in seven large countries with 420 million inhabitants. It is obvious that there are large differences corresponding to resources available in the respective countries. Allogeneic transplant rates (Figure 5a ) continue to increase particularly in Germany, France, Italy and the United Kingdom and to a lesser extent in Spain, Turkey and Poland. Rates of autologous transplantations (Figure 5b ) appear to have reached a plateau in Germany, France and Italy at a rate of 330-420 per 10 million inhabitants but continue to increase in Poland and Turkey.
Analysis of seven large European countries
There are particular differences that cannot be explained easily. Unrelated donor transplantation in CR1 of AML is particularly frequent in Germany, more so than in France and Italy (transplant rates of 31, 22 and 20 per 10 million for Germany, France and Italy, respectively) possibly reflecting the important investment in donor registries in Germany making unrelated donors more easily available. Even more striking are differences in the use of alternative donors such as cord blood (Figure 6a ), used commonly in France and Spain and only rarely in Germany, whereas Italy and Germany are leading the field in transplants from mismatched related donors (Figure 6b ). Unrelated donor cord-blood use appears to be in competition with haploidentical donor transplantation for patients without a sibling or a matched unrelated donor.
Figures 7a and b show rates of allogeneic and autologous transplantation for four indications, AML, Non Hodgkin's lymphoma (NHL), Hodgkin's disease (HD) and PCDs for the seven countries. It is evident that next to economic resources, other factors seem to have a role in the selection of treatment for patients. If we compare which countries are leading the field per indication, it becomes evident that for AML autologous HSCT it is Italy and Spain, for HD it is Italy before Spain, for NHL it is France and Italy and for PCD it is Germany and France. For allogeneic HSCT, it is Germany and Italy for AML, Italy and the United Kingdom for HD, Germany and Italy for NHL and Germany and France for PCD. For instance, Germany is ranked first in allogeneic HSCT for NHL but fifth out of seven for HD. Such differences require explanation and suggest a lack of consensus about transplant indications, but probably reflect also discrepancies in general treatment algorithms for 'transplantable' diseases between large European countries.
DISCUSSION
The EBMT activity survey has been conducted annually since 1990. As this spans two decades in 2010, we show here not only the data pertaining to the 2010 survey but also a review of the development since 1990. Added is a seven-country comparison in transplant rates highlighting important differences between European countries. 97  98  99  00  01  02  03   Year   04  05  06  07  08  09  10  97  98  99  00  01  02  03   Year   04  05  06  07  08  09  10 Cord blood donor HLA haploidentical sibling donors The 2010 survey has for the first time reported more than 30 000 patients transplanted in a given year. This is almost ten times more than the 4,200 patients reported in 1990 and shows that HSCT is a dynamic procedure with continued growth even though certain types of transplants have been abandoned since; note the high number of patients with breast cancer that underwent autologous HSCT in the early 90s or the decline of CML as a prime indication since 2000.
The observed increase is multifactorial and appears to be due to developing indications for allogeneic HSCT, that is, MDS/MPS, CLL and lymphoid neoplasias, the increasing age of allogeneic transplant patients with the introduction of RIC regimens (most diseases treated have a median age of onset of 460 years), the availability of new donor sources, in particular, the huge increase in unrelated donors tested and available, which is now 419 million donors, the availability of cord blood units through the cord blood banks and resource-poor countries achieving a financial situation that permits investment in this expensive technology.
For autologous HSCT, there is a similar but weaker trend to increased numbers. Autologous HSCT is currently considered part of standard first-line therapy in PCD and second-line treatment in aggressive lymphomas. This may change somewhat in the future given the development of new drugs for these disorders.
These changes emphasize the necessity of continuously re-evaluating transplant indications, which is an important activity of the EBMT through this survey but also through the huge investment in observational research based on the EBMT Registry database. [16] [17] [18] [19] [20] [21] [22] [23] This survey is also useful to document changes in practice because of knowledge gained through studies. This is exemplified by the drastic reduction of autologous HSCT for breast cancer, the decline of CML for which HSCT nowadays is mostly used after failure of tyrosine kinase inhibitors, but also the reversal of the trend toward increasing use of peripheral blood in allogeneic HSCT for marrow failure after publication of data showing that marrow was associated with lower chronic GVHD risks. We hope that the trend towards allogeneic transplants for CML being done after transformation to advanced phase will be reversed as well.
Evidently, predictions as to further development is difficult. As shown in Figure 5b , the numbers of autologous HSCT appear to level-off in the resource-rich countries, whereas the resource-poor countries continue to increase their number. The number of allogeneic HSCT continue to grow and it is of interest that there are large differences between countries, with countries of the former Eastern Block and of the Balkans lagging behind Western Europe. It is likely that transplant rates in these resource-poor countries will increase in the near future. It is of equal interest that the indications for HSCT differ among countries, this is true for the type of transplantation, such as unrelated cord blood or haploidentical HSCT, which are used differently in different countries, and also for the indications of particular diseases, for example, allogeneic HSCT for HD, used more commonly in the UK, and for myeloma, used more frequently in Germany. These differences are probably best explained by attitudes of collaborative groups and by protocols advancing one or the other indication as there is little evidence that disease incidence differs among countries to such an extent. It is important to highlight such differences and these data may be useful for discussion within the EBMT and transplant community. 
